J. Behr, S. Nathan, S. Harari, W. Wuyts, K. Kirchgaessler, M. Bengus, F. Gilberg, A. Wells
{"title":"西地那非加吡非尼酮治疗晚期特发性肺纤维化(IPF)和肺动脉高压(PH)的风险:PH关键评估分析(右心导管可用性和基线NT-proBNP)","authors":"J. Behr, S. Nathan, S. Harari, W. Wuyts, K. Kirchgaessler, M. Bengus, F. Gilberg, A. Wells","doi":"10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1913","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":333033,"journal":{"name":"TP28. TP028 APPROACH TO THERAPY IN FIBROSING AND NON-FIBROSING ILD","volume":"10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH): Analysis of PH Key Assessments (Right Heart Catheterization Availability and Baseline NT-proBNP)\",\"authors\":\"J. Behr, S. Nathan, S. Harari, W. Wuyts, K. Kirchgaessler, M. Bengus, F. Gilberg, A. Wells\",\"doi\":\"10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1913\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":333033,\"journal\":{\"name\":\"TP28. TP028 APPROACH TO THERAPY IN FIBROSING AND NON-FIBROSING ILD\",\"volume\":\"10 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"TP28. TP028 APPROACH TO THERAPY IN FIBROSING AND NON-FIBROSING ILD\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1913\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"TP28. TP028 APPROACH TO THERAPY IN FIBROSING AND NON-FIBROSING ILD","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1913","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH): Analysis of PH Key Assessments (Right Heart Catheterization Availability and Baseline NT-proBNP)